Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Capital Employed (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Return on Capital Employed for 12 consecutive years, with 0.73% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 50.0% to 0.73% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.73% through Dec 2025, down 50.0% year-over-year, with the annual reading at 0.85% for FY2025, 67.0% down from the prior year.
  • Return on Capital Employed hit 0.73% in Q4 2025 for Coherus Oncology, down from 0.25% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.1% in Q1 2021 to a low of 1.28% in Q1 2024.
  • Historically, Return on Capital Employed has averaged 0.55% across 5 years, with a median of 0.57% in 2023.
  • Biggest five-year swings in Return on Capital Employed: tumbled -78bps in 2021 and later surged 114bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.48% in 2021, then crashed by -41bps to 0.68% in 2022, then dropped by -9bps to 0.74% in 2023, then surged by 68bps to 0.23% in 2024, then plummeted by -214bps to 0.73% in 2025.
  • Business Quant data shows Return on Capital Employed for CHRS at 0.73% in Q4 2025, 0.25% in Q3 2025, and 0.2% in Q2 2025.